REG - Venture Life Group - Trading Update

Venture LifeAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260126:nRSZ2485Qa&default-theme=true

RNS Number : 2485Q  Venture Life Group PLC  26 January 2026

26 January 2026

 

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Group")

 

Trading Update

 

Venture Life (AIM: VLG), a leader in product innovation, development and
commercialisation within the global consumer healthcare sector, announces a
trading update for the twelve-month period ended 31 December 2025 (the
"Period"). As announced on 24 September 2025, the Company has changed its
accounting reference date from 31 December to 31 May, and will publish
unaudited interim accounts for the Period on 31 March 2026.

 

The Group delivered revenues(1) of £35.1 million during the Period,
representing a 32.0% increase compared to the previous year (FY24: £26.6
million). On a proforma(2) basis, which assumes acquisitions were in place for
the entirety of the prior year, revenues were up 11.1% year-on-year,
comprising 0.9% from price increases and 10.2% from volume sold.

 

The Power Brands (Balance Activ, Lift/Glucogel, Earol, Health & Her/Him)
grew 14.9% to £33.1 million (FY24 proforma: £28.8 million). Underlying this
was strong performance in the UK where increased investment in advertising and
promotion ("A&P") drove revenue growth of 20.7% to £25.7 million (FY24
proforma: £21.3 million). The international business declined 8.7% to £9.4
million (FY24 proforma: £10.3 million) and was attributable to order timing
from partners.

 

The strong growth in UK revenues came from increases to Balance Activ of 37.0%
to £4.3 million (FY24: £3.2 million) and Earol of 11.5% to £3.2 million
(FY24: £2.8 million). The Lift brand demonstrated a strong recovery in the
second half of the year, finishing with a 4.9% increase to £7.3 million
(FY24: £7.0 million). The Health & Her/Him brands, which were acquired on
8 November 2024, delivered significant proforma growth of 44%, reaching £8.5
million (FY24 proforma: £5.9 million; FY24 reported: £0.8 million).

 

The reduction in the international business was primarily driven by two
factors: Firstly, the largest partner for Gelclair moved a significant order
into early 2026. Secondly, there were high stock levels in-market for Earol
(sold under the Vaxol brand) in Scandinavia, and operations were temporarily
disrupted as a result of a recent change in ownership of the in-market local
distributors. This has now been resolved and new market expansion
opportunities are also under discussion.

 

As communicated during 2025 following the disposal of its CDMO operations, VLG
is now a pure branded consumer healthcare business, focused on the growth and
development of its brands. The future development of the international
business will be focused on growing key strategic partnerships with larger
counterparties in key markets, which will bring more stability and
predictability to international revenues and profitability. As part of this
focus, the decision was taken to close the Spanish office that managed these
international partners, and incorporate this function within the UK based
commercial team. This alignment with brand strategy in the UK and the building
of bigger and more select strategic partnerships is expected to deliver
greater and more stable long term value for Venture Life's brands outside of
the UK.

 

In addition to increasing A&P activities, investment and resource has been
increased in the area of new product development ("NPD"). Led by Kate Bache,
Chief Innovation Officer, this focus is fundamental to brand success and value
growth. In conjunction with our strategic partnership with the Healthea Group,
the owner of BioDue S.p.A which acquired the CDMO business in July 2025, this
has seen the development of a deep and exciting NPD pipeline which is expected
to deliver meaningful revenue growth in the future. Further, following the
appointment of Peter Jackson to the Board at the end of 2025, the Group has
begun investing in integrated digital technologies and has successfully
launched the new Microsoft Dynamics 365 ERP system. This will support the
execution of the Group's new data and digital led strategy which is beginning
to drive efficiencies across the organisation.

 

The Company continues to pursue immediately earnings enhancing M&A
opportunities and is actively working on a number of potential targets within
complimentary sectors across women's health, men's health, energy management
and hormonal health. Further updates will be provided as and when appropriate.

 

As at 31 December 2025, the Company held a net cash position of £34.4 million
(30 June 2025: £2.0 million) (30 September 2025: £34.1 million). The
Company's share buyback programme that was announced on 30 September 2025
remains ongoing, and as at 31 December 2025 a total of £1.1 million had been
returned to shareholders through the acquisition of approximately 1.7 million
ordinary shares. The Board remains confident in achieving management's revenue
and Adjusted EBITDA expectations for the seventeen-month accounting period
ending 31 May 2026.

 

(1) Revenue from continuing operations excluding the divested CDMO business,
non-core products and oral care brands.

(2) Proforma basis i.e. if the acquisitions had been in place for the whole of
the prior year.

 

Jerry Randall, CEO, commented:

"Our decision to meaningfully increase A&P spend in the UK during 2025 has
been vindicated by the revenue growth seen across the Power Brands which are
well ahead of sector norms. The growth in our women's health brands is
particularly pleasing, as we see this category as a key value driver in the
future, and I am delighted with the performance of the Health & Her
business acquired in late 2024. Since the divestment of our CDMO business we
have invested significantly to both backfill certain positions that were
previously run from within the CDMO business, and build the infrastructure
with strong talent to support our growth aspirations and enhance capabilities.

 

We have also restructured and refocused the international business with a view
to this delivering more stable and consistent profitable growth through key
strategic partnerships. 2025 was a period of significant change and sharpening
of focus which has pivoted the Group to become a pure branded consumer
healthcare business focused on supporting consumers in proactive healthy
longevity. We have entered 2026 with great momentum and with a reshaped
focused business setup for our future aspirations as well as being very active
in pursuing the right M&A opportunities to leverage our enhanced
capabilities and resources. I am very excited about the opportunities in front
of us and look forward to updating shareholders more in due course."

 

 

For further information, please contact:

 

Venture Life Group
PLC
                +44 (0) 1344 578004

 

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and
Broker)
           +44 (0) 20 7720 0500

 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

 

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in
the UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health & Her product range supporting the hormonal lifecycle.

 

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK,  Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTAKQBPOBKDODB



            Copyright 2019 Regulatory News Service, all rights reserved